SCANCELL HOLDINGS PLC
Scancell Holdings plc is a public limited company incorporated in England and Wales on 14 April 2008 under company number 06564638, with its registered office at the Bellhouse Building, Sanders Road, Oxford Science Park, Oxford, OX4 4GD. According to Companies House, its current registry status is active.
Scancell Holdings plc is the holding company of a clinical-stage biopharmaceutical group that discovers and develops novel immunotherapies for the treatment of cancer. Its registered business activities, as classified by Companies House, are research and experimental development on natural sciences and engineering (SIC 72190) and other human health activities (SIC 86900). The group’s pipeline includes SCIB1/iSCIB1+, a DNA-based immunotherapy in clinical development for melanoma; Modi-1 and Modi-2, peptide immunotherapies targeting stress-induced post-translational modifications in solid tumours including renal, head and neck, ovarian and triple-negative breast cancer; and the GlyMab and AvidiMab antibody platforms, which target glycan and immune-signalling mechanisms on cancer cells.
Scancell Holdings plc’s ordinary shares trade on the AIM market of the London Stock Exchange under the ticker SCLP. In its results for the year ended 30 April 2025, the Group reported consolidated revenue of £4.7 million, arising from a licensing collaboration with Genmab A/S, against an operating loss of £15.0 million and an overall Group loss of £12.3 million for the period; year-end cash was reported at £16.9 million. These figures relate to the consolidated Group rather than to Scancell Holdings plc on an unconsolidated basis.
On 23 July 2026, Scancell Holdings plc announced a proposed all-share merger with the US biopharmaceutical company Neuphoria Therapeutics Inc., alongside a financing package of up to approximately $89 million intended to fund a Phase 3 trial of iSCIB1+ and extend the Group’s cash runway into 2029. The transaction, which is intended to give the combined group a Nasdaq listing alongside its existing AIM listing, remained subject to shareholder approval and regulatory clearance as of the most recent announcements, with completion targeted for the fourth quarter of calendar year 2026.
- Company fundamentals
- Corporate linkage & group structures
- Digitized company financials
- Firmographics — websites, social profiles, revenue and employee estimates
Shareholders
Shareholders of SCANCELL HOLDINGS PLC
As a UK public limited company, Scancell Holdings plc’s beneficial-ownership disclosure comes from the Persons with Significant Control (PSC) register maintained by Companies House rather than a full public share register. As of the PSC filing dated 2 November 2020, the company’s only registered PSC is Mr Jeremy Charles Green, recorded as holding more than 25% but not more than 50% of shares and of voting rights, and as having the right to appoint or remove directors. No percentage more precise than this statutory band is disclosed.
Separately, under AIM Rule 17 substantial-shareholding notifications, Redmile Group, LLC — a US-based healthcare and life-sciences investment manager — disclosed on 30 July 2026 that funds it manages, including RedCo I, L.P. and Redmile Biopharma Investments II, L.P., held 24.52% of Scancell Holdings plc’s voting rights following a threshold crossing on 28 July 2026, down from a previously notified 28.95%. This is a disclosed institutional shareholding under AIM disclosure rules rather than a Companies House PSC registration, and Redmile Group, LLC does not currently appear on Scancell Holdings plc’s PSC register.
No other individual or corporate shareholding above the relevant disclosure thresholds was identified from official sources at the time of research.
Ultimate beneficial ownership
Mr Jeremy Charles Green is identified by Companies House as a beneficial owner of Scancell Holdings plc, holding a direct interest of more than 25% but not more than 50% of shares and voting rights, with the right to appoint or remove directors, as notified on 2 November 2020. Redmile Group, LLC’s disclosed 24.52% voting-rights holding is managed through investment funds; no natural person has been identified from official sources as the ultimate beneficial owner behind that holding, so it is not treated as a UBO position here.
Data availability
Shareholder and beneficial-ownership information for this company is major shareholders only: the Companies House PSC register discloses interests crossing statutory thresholds (25%, 50%, 75%) rather than a complete shareholder list, and AIM Rule 17 notifications disclose only shareholdings crossing the 3% reporting threshold. A complete register of all shareholders is not publicly available.
Sources
- Companies House — Persons with Significant Control, Scancell Holdings Plc — https://find-and-update.company-information.service.gov.uk/company/06564638/persons-with-significant-control — filed 2 November 2020 — retrieved 11 September 2026
- Investegate — Holding(s) in Company RNS, Scancell Holdings plc — https://www.investegate.co.uk/announcement/rns/scancell-holdings–sclp/holding-s-in-company/9699437 — published 30 July 2026 — retrieved 11 September 2026
- Companies House — Company overview, Scancell Holdings Plc — https://find-and-update.company-information.service.gov.uk/company/06564638 — retrieved 11 September 2026
Officers
22
Directors and officers of SCANCELL HOLDINGS PLC
Companies House records eight active officers of Scancell Holdings plc: seven directors and one company secretary. The current directors are Susan Elizabeth Clement Davies (appointed 24 September 2020), Professor Linda Gillian Durrant (appointed 16 April 2008, at incorporation), Dr Ursula Mary Ney (appointed 23 October 2019), Martin Henry Diggle (appointed 18 June 2019), Dr Jean-Michel Cossery (appointed 1 February 2023), Dr Florian Nicolas Christian Reinaud (appointed 9 July 2024) and Dr Phillip John L’Huillier (appointed 18 November 2024). Alexander Hayward was appointed Company Secretary on 24 April 2026. Companies House also lists twenty former officers, reflecting a long history of board and secretarial changes since incorporation in 2008. This overview reflects officer data retrieved from Companies House on 11 September 2026; nationality and country-of-residence fields are disclosed for individual directors under the UK filing regime but are not published for corporate officers.
Recent officer changes
- Alexander Hayward was appointed Company Secretary on 24 April 2026, the same date Sathijeevan Nirmalananthan’s appointment as Company Secretary ended. Source: Companies House officers register.
- Dr Phillip John L’Huillier was appointed as a director on 18 November 2024. Source: Companies House officers register.
- Dr Florian Nicolas Christian Reinaud was appointed as a director on 9 July 2024. Source: Companies House officers register.
Data availability
Officer information for UK companies is full: Companies House publishes current and historical director and secretary appointments with appointment and resignation dates. Nationality is disclosed for individual officers — British, French and New Zealander nationalities are recorded among current directors — while country of residence is recorded separately and must not be inferred from nationality, correspondence address or role. Correspondence addresses shown for officers are service addresses, not home addresses.
Sources
- Companies House — Officers, Scancell Holdings Plc — https://find-and-update.company-information.service.gov.uk/company/06564638/officers — retrieved 11 September 2026
Registry feed — rows exactly as filed with Companies House, including entries the profile above does not cover.
Group Structure
Group structure of SCANCELL HOLDINGS PLC
Scancell Holdings plc’s own Persons with Significant Control register does not identify any corporate parent; its sole registered PSC is an individual, Mr Jeremy Charles Green (see Shareholders). No immediate or ultimate corporate parent of Scancell Holdings plc has been verified from official sources at the time of research. Companies House confirms two verified direct subsidiaries: Scancell Limited (company number 03234881), the group’s original operating company, incorporated on 7 August 1996; and GlyMab Therapeutics Limited (company number 16538942), incorporated on 24 June 2025. Both entities are UK-registered private limited companies sharing Scancell Holdings plc’s Oxford registered address, and both list Scancell Holdings Plc as their sole PSC with 75% or more of shares and voting rights. A US-based investment manager, Redmile Group, LLC, is a substantial shareholder in Scancell Holdings plc through managed funds (see Shareholders), but this is a disclosed shareholding, not a verified parent-subsidiary relationship, and Redmile Group, LLC does not appear on Scancell Holdings plc’s own PSC register.
Verified corporate relationships
| Entity | Country | Registration number | Relationship | Ownership | Status | Information date |
|---|---|---|---|---|---|---|
| Scancell Limited | United Kingdom | 03234881 | Direct subsidiary | 75% or more of shares and voting rights | Active | 6 April 2016 (PSC notified date) |
| GlyMab Therapeutics Limited | United Kingdom | 16538942 | Direct subsidiary | 75% or more of shares and voting rights | Active | 24 June 2025 (PSC notified date) |
Recent structural changes
- Proposed merger: on 23 July 2026, Scancell Holdings plc announced a proposed all-share merger with Neuphoria Therapeutics Inc., together with an associated financing package. The transaction had not completed as of the most recent available announcements and remained subject to shareholder approval and regulatory clearance, with completion targeted for the fourth quarter of calendar year 2026. Source: Investegate RNS, Merger and Financing, 23 July 2026.
Data availability
Corporate-linkage information for this company is partial: UK PSC filings confirm two direct subsidiaries and rule out a registered corporate parent for Scancell Holdings plc itself, but do not disclose ownership below the subsidiaries or confirm whether either subsidiary has further subsidiaries of its own. The proposed Neuphoria merger, if completed, would materially change this structure and is not yet reflected as a completed relationship.
Sources
- Companies House — Persons with Significant Control, Scancell Holdings Plc — https://find-and-update.company-information.service.gov.uk/company/06564638/persons-with-significant-control — retrieved 11 September 2026
- Companies House — Persons with Significant Control, Scancell Limited — https://find-and-update.company-information.service.gov.uk/company/03234881/persons-with-significant-control — filed 6 April 2016 — retrieved 11 September 2026
- Companies House — Persons with Significant Control, GlyMab Therapeutics Limited — https://find-and-update.company-information.service.gov.uk/company/16538942/persons-with-significant-control — filed 24 June 2025 — retrieved 11 September 2026
- Investegate — Merger and Financing RNS, Scancell Holdings plc — https://www.investegate.co.uk/announcement/rns/scancell-holdings–sclp/merger-and-financing/9683817 — published 23 July 2026 — retrieved 11 September 2026
Redmile Group, LLC
United States
Get complete shareholder and officer records, ultimate beneficial owner resolution, and ongoing ownership monitoring.
Frequently Asked Questions
What does SCANCELL HOLDINGS PLC do?
Scancell Holdings plc is a clinical-stage biopharmaceutical company incorporated in England and Wales in 2008, developing novel cancer immunotherapies including SCIB1/iSCIB1+, Modi-1, Modi-2 and the GlyMab antibody platform, headquartered in Oxford.
Who owns SCANCELL HOLDINGS PLC?
Companies House records Jeremy Charles Green as the sole registered Person with Significant Control, holding more than 25% but not more than 50% of shares and voting rights since 2 November 2020. Redmile Group, LLC, a US healthcare investment manager, separately disclosed a 24.52% voting-rights stake via AIM Rule 17 notification on 30 July 2026, though it does not appear on the PSC register.
Who is SCANCELL HOLDINGS PLC's UBO (Ultimate Beneficial Owner)?
The identified beneficial owner is Jeremy Charles Green, a British national whom Companies House records as holding a direct interest of more than 25% but not more than 50% of shares and voting rights, notified 2 November 2020. No more precise percentage is disclosed.
What is SCANCELL HOLDINGS PLC's company registration number?
SCANCELL HOLDINGS PLC's registration number is 06564638, filed with Companies House in United Kingdom. Its current status on the register is active.
Is SCANCELL HOLDINGS PLC still an active company?
SCANCELL HOLDINGS PLC's status on Companies House is listed as active.
When was SCANCELL HOLDINGS PLC incorporated?
SCANCELL HOLDINGS PLC was incorporated on 14 April 2008, according to Companies House.
What is SCANCELL HOLDINGS PLC's registered address?
The registered address on file for SCANCELL HOLDINGS PLC is Oxford, United Kingdom.
What legal structure is SCANCELL HOLDINGS PLC registered as?
SCANCELL HOLDINGS PLC is registered as a Public Limited Company in United Kingdom.
What is SCANCELL HOLDINGS PLC's revenue?
For the year ended 30 April 2025, the Group reported consolidated revenue of £4.7 million (2024: nil) from a licensing collaboration with Genmab A/S, an operating loss of £15.0 million and an overall Group loss of £12.3 million.
Is SCANCELL HOLDINGS PLC listed on a stock exchange?
Scancell Holdings plc is listed on the AIM market of the London Stock Exchange under ticker SCLP. In July 2026 it announced a proposed merger with Neuphoria Therapeutics Inc. and an approximately $89 million financing package intended to add a Nasdaq listing, subject to shareholder and regulatory approval.
Who are the officers/directors of SCANCELL HOLDINGS PLC?
Companies House lists eight active officers, including seven directors — among them Professor Linda Durrant, a director since incorporation in 2008, and Dr Phillip L'Huillier, appointed in 2024 — and Company Secretary Alexander Hayward, appointed 24 April 2026, alongside twenty former officers.
Does SCANCELL HOLDINGS PLC have a parent company or subsidiaries?
No corporate parent of Scancell Holdings plc is registered at Companies House; its only PSC is an individual shareholder. Two verified direct subsidiaries are confirmed by PSC filings: Scancell Limited and GlyMab Therapeutics Limited, both UK-registered and majority-owned (75% or more) by Scancell Holdings plc.
Can Zavia monitor changes to SCANCELL HOLDINGS PLC's ownership over time?
This profile reflects a point-in-time snapshot from Companies House. Zavia's monitoring API can track changes to SCANCELL HOLDINGS PLC's registered shareholders, officers, and group structure going forward, flagging updates as they're filed rather than requiring a manual recheck.
Can I access SCANCELL HOLDINGS PLC's data through an API?
Yes. Zavia's API connects directly to official government ownership registries across 195 countries and territories, including United Kingdom, so records like SCANCELL HOLDINGS PLC's registration, shareholder, UBO, and group-structure data can be queried programmatically instead of viewed one page at a time.
Where does this company information come from, and how current is it?
This record is sourced directly from Companies House and was last synced on 8 September 2026.